Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

OGX-427 in Castration Resistant Prostate Cancer Patients

Phase 2

Completed

Conditions: Castration Resistant Prostate Cancer

Interventions: Drug: OGX-427
Drug: Prednisone

First Posted Date: 2010-05-11

Last Posted Date: 2019-02-15

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 74

Registration Number: NCT01120470

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦
BC Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 3 locations

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: PEG-L-asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: mercaptopurine
Drug: ifosfamide
Drug: methotrexate
Drug: vincristine sulfate
Drug: prednisone
Radiation: Radiation Therapy
Drug: thioguanine
Drug: vindesine
Drug: daunoxome
Drug: fludarabine

First Posted Date: 2010-05-05

Last Posted Date: 2022-05-24

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 6136

Registration Number: NCT01117441

Locations: 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿
University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪
Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany

and more 134 locations

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Phase 2

Terminated

Conditions: Myeloma

Interventions: Drug: dasatinib
Drug: melphalan
Drug: prednisone

First Posted Date: 2010-05-04

Last Posted Date: 2011-06-14

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 8

Registration Number: NCT01116128

Locations: 🇮🇹
Mario Boccadoro, Torino, Italy

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone
Drug: LHRHa

First Posted Date: 2010-03-17

Last Posted Date: 2014-05-15

Lead Sponsor: Cougar Biotechnology, Inc.

Target Recruit Count: 66

Registration Number: NCT01088529

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Phase 2

Completed

Conditions: Systemic Sclerosis-Associated PAH

Interventions: Biological: Rituximab
Other: Placebo
Diagnostic Test: CMRI
Drug: prednisone
Drug: methylprednisolone
Drug: diphenhydramine
Drug: acetaminophen

First Posted Date: 2010-03-15

Last Posted Date: 2023-02-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT01086540

Locations: 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸
University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

and more 14 locations

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: TAK-700
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2010-03-10

Last Posted Date: 2019-07-30

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 38

Registration Number: NCT01084655

Locations: 🇺🇸
Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3

Terminated

Conditions: Hormone Refractory Prostate Cancer
Castrate-Resistant Prostate Cancer

Interventions: Drug: isotonic, 0.9% sodium chloride
Drug: custirsen sodium
Drug: docetaxel
Drug: cabazitaxel
Drug: prednisone

First Posted Date: 2010-03-10

Last Posted Date: 2016-10-12

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 14

Registration Number: NCT01083615

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Prednisone

First Posted Date: 2010-02-25

Last Posted Date: 2014-02-19

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 2728

Registration Number: NCT01075711

Locations: 🇩🇪
Merck Serono GmbH, Darmstadt, Germany, Darmstadt, Germany

Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma

Phase 2

Completed

Conditions: Hemangioma

Interventions: Drug: Prednisone
Drug: Propranolol

First Posted Date: 2010-02-19

Last Posted Date: 2014-12-02

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 50

Registration Number: NCT01072045

Locations: 🇧🇷
Instituto de Tratamento do Câncer Infantil (Pediatric Cancer Treatment Institute) - ITACI - ICr-HCFMUSP (Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Sao Paulo, Brazil

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-01-22

Last Posted Date: 2021-10-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT01054144

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy